UK Pays 30% More for Drugs Under New US Deal

By VirentaNews Staff — May 18, 2026

In a move that could reshape the future of public healthcare in the UK, two leading health campaign groups are threatening the government with legal action over a controversial pharmaceutical agreement with the United States. The deal, negotiated in secret and linked to broader trade talks during Donald Trump’s presidency, could force the NHS to pay up to 30% more for life-saving medicines, according to internal estimates seen by advocates. This surge in drug costs would not only strain an already overburdened health system but may violate existing laws governing how medicines are assessed for public funding. With the National Health Service spending over £20 billion annually on prescriptions, even a modest percentage increase could redirect billions away from frontline care, staff, and innovation—putting patient access and equity at risk.

Behind the UK-US Pharmaceutical Agreement

The controversy centers on a little-publicized change to the way the NHS evaluates new medicines through the National Institute for Health and Care Excellence (NICE). Campaigners argue that the UK-US agreement, finalized in late 2025, includes provisions that effectively bypass NICE’s independent cost-effectiveness assessments, allowing pharmaceutical companies to demand higher prices without transparent justification. This shift, they claim, undermines decades of evidence-based decision-making that have kept NHS drug spending sustainable. The agreement was negotiated under the guise of a zero-tariff pharmaceuticals deal, but its implications extend far beyond trade—it strikes at the heart of how the UK values public health versus corporate profit. With growing concerns about transparency and democratic oversight, the timing couldn’t be more critical: the NHS is already grappling with record waiting lists, workforce shortages, and budget constraints.

The Legal Challenge to NHS Drug Approval Changes

The two campaign groups—Health Justice UK and Patients Not Profits—have issued a formal legal notice to the Department of Health and Social Care, demanding the suspension of the new drug pricing mechanism. They argue that transferring pricing authority from NICE to a bilateral UK-US committee constitutes an “unlawful power grab” that violates the National Health Service Act 2006, which mandates that treatments be made available based on clinical and economic evidence. The groups cite leaked documents suggesting that the new framework prioritizes U.S. pharmaceutical industry demands over patient outcomes, allowing American drugmakers to invoke dispute settlement clauses if their prices are rejected. This undermines the NHS’s ability to negotiate fairly and could lock the UK into long-term, inflated contracts for drugs that offer minimal clinical benefit over existing options.

Why Drug Pricing Autonomy Matters for Public Health

The core of the dispute lies in the principle of health sovereignty: the right of a nation to determine how its public health resources are spent. The UK has long maintained a rigorous, independent evaluation process through NICE, which compares new drugs to existing treatments and considers both clinical benefit and cost. This model has allowed the NHS to provide cutting-edge therapies while controlling expenditure—unlike the U.S., where drug prices are among the highest in the world. According to the World Health Organization, unchecked pharmaceutical pricing is a global driver of healthcare inequity. By aligning its pricing framework with U.S. norms, the UK risks eroding its own standards and setting a dangerous precedent for future trade deals. Experts warn that if the agreement stands, it could deter investment in generic alternatives and discourage innovation in cost-effective therapies.

Implications for Patients and the NHS

If the new pricing regime takes full effect, hundreds of thousands of NHS patients could face delays or denials in accessing new treatments, not due to medical reasons, but financial ones. Hospitals may be forced to ration care or divert funds from mental health, cancer screening, and preventive programs to cover spiraling drug costs. The burden would fall hardest on those with rare diseases or chronic conditions requiring expensive biologics. Additionally, the loss of NICE’s gatekeeping role could weaken public trust in the fairness of the healthcare system. With inflation already driving up operational costs, the NHS cannot afford unpredictable drug pricing. Campaigners stress that this isn’t just a technical regulatory issue—it’s a fundamental question of whether healthcare should be guided by public interest or international trade obligations.

Expert Perspectives

Health economists are divided on the long-term impact. Dr. Amina Khan of the London School of Hygiene & Tropical Medicine warns that “abandoning evidence-based appraisal risks turning the NHS into a price-taker, not a price-setter.” In contrast, trade policy analyst James Foley from Chatham House argues that some alignment with U.S. standards could attract pharmaceutical investment and speed up drug availability. However, even he concedes that “transparency and safeguards are essential—this deal lacks both.” Patient advocacy groups overwhelmingly side with the campaigners, emphasizing that any trade benefit must not come at the cost of healthcare access.

As the legal showdown looms, all eyes are on the government’s response. Will it defend the deal in court, or revise its approach to protect NHS autonomy? The outcome could define the future of public healthcare in Britain and influence how other nations balance trade agreements with health rights. With a judicial review potentially on the horizon, the question remains: can the NHS remain a publicly accountable system if its drug prices are dictated by transatlantic negotiations?

Source: The Guardian